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Abstract: Dupuytren’s disease (DD) is a type of fibromatosis which progressively results in the shortening and thickening 
of the fibrous tissue of the palmar fascia. This condition which predominantly affects white-northern Europeans has been 
identified since 1614. DD can affect certain activities of daily living such as face washing, combing hair and putting hand 
in a glove. The origin of Dupuytren’s contracture is still unknown, but there are a number of treatments that doctors have 
come across throughout the years. Historically surgery has been the mainstay treatment for DD but not the only one. The 
objective is to make a structured review of the  most recent advances in treatment of DD including the surgical and 
medical interventions. We have looked at the most relevant published articles regarding the various treatment options for 
DD. This review has taken 55 articles into consideration which have met the inclusion criteria. The most recent treatments 
used are multi-needle aponeurotomy, extensive percutaneous aponeurotomy and lipografting, injecting collagenase 
Clostridium histolyticum, INF-gamma and shockwave therapy as well as radiotherapy. Each of these treatments has 
certain advantages and drawbacks and cannot be used for every patient. In order to prevent this condition, spending more 
time and money in the topic is required to reach better and more consistent treatments and ultimately to eradicate this 
disease. 
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BACKGROUND INFORMATION 
  The first doctor who came across this condition was 
Plater in 1614 [1]. In 1831 a French military surgeon called 
Guillaume Dupuytren became famous for describing and 
operating on palmar fibromatosis, which is now commonly 
known as Dupuytren’s disease. The disease is described as a 
type of fibromatosis characterized by nodular and/or 
distributed aggregates of immature fibroblasts dispersed in a 
dense collagen [2]. The progressive and irreversible flexion 
contractures of the phalangeal joints of the hand are the 
nature of this disease. These flections which predominantly 
affect the small and ring finger are due to the proliferation of 
myofibroblasts in the fascia of the hand. Myofibroblasts 
were the first responsible cause for contracture in this 
disease. It was first due to their ultrastructural identification 
in transmission electron-microscopic studies but later on 
scientists showed that the contracture was mainly due to the 
expression of Alpha-smooth muscle actin (SMA) in cells 
from tissue explants. Furthermore, it was shown that 
myofibroblasts can generate contractile force [3, 4]. 
EPIDEMIOLOGY 
  Looking at the incidence of Dupuytren’s disease (DD), 
white-northern Europeans have the highest rate whereas   
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dark-skinned individuals have the lowest number of 
occurrences [5, 6]. Twin studies have shown that there is 
some evidence supporting the theory that this disease could 
be a familial disorder [7]. It is still uncertain whether 
Dupuytren’s disease is a monogenic or a polygenic condition 
as this condition has variable inheritance patterns and 
different levels of gene expression. 
  Scandinavians and people with Northern European 
ancestry were mainly responsible for the spread of this 
disease hence it is being called the “Viking disease” [8]. The 
theory of Nordic origin of the disease can be supported by 
the high incidence rate among the people in Denmark as well 
as in the northern part of the UK [9]. 
  Both age and sex, have an effect on the occurrence of 
Dupuytren’s disease. The incidence is very low among teens 
and people in their twenties but the risk of having this 
condition increases each decade. According to Mikkelsen et 
al. the onset of Dupuytren’s contracture (DC) is indirectly 
proportional to the recurrence and progression of this 
disease. In other words the earlier the onset of the disease the 
more likely the recurrence and progression of Dupuytren’s 
contracture in the future [10, 11] Men are up to 15 times 
more likely to suffer from this disease. DC however, is less 
sever in women and may even remain unnoticed. During the 
8
th and 9
th decade of life the ratio between affected men and 
women is equal [11]. 
  There is mixed evidence as to what the causes and 
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agree on a well-established link between this disease and 
diabetes mellitus (DM). Patients who develop Dupuytren’s 
disease and suffer from DM have more nodules and less 
contraction [12]. There is no reliable evidence for other 
diseases such as liver disease, TB, syphilis, high serum lipids 
and HIV+ to be associated with Dupuytren’s contracture. 
There is a degree of controversy as to whether there is an 
association between epilepsy, smoking and alcohol intake 
and Dupuytren’s disease. There are a considerable number of 
individuals suffering from this condition who have never 
smoked or drank alcohol. Moreover, a direct link between 
work-related activities such as using vibrating machines and 
increasing risk of Dupuytren’s disease has not been 
established [13,14]. One statistical finding that should not be 
underestimated is that 42% of people with severe DC died of 
cancer. It is evident that more investigation is needed to 
confirm what can be the cause of this disease and for the 
time being the patients should be told that the cause of this 
condition is unknown [15]. 
THE DISEASE PROCESS 
  The known process of the disease is similar to wound 
healing which involves the proliferation of the fibroblasts 
and deposition of the collagen and myofibroblast 
contraction. This process works with the aid of a number of 
growth factors such as transforming growth factor Beta [16, 
17]. Bands of fascial fibres, which are lining longitudinally 
in the subcutaneous tissue of the palm that anchor the skin of 
the palm grow thick fibrous cords which result in the 
contraction of the digits [18]. Scientists have found 
similarities between the presenting features of neoplastic 
process and Dupuytren’s disease. They both include specific 
chromosomal defects and high rates of recurrence post 
surgery [16, 17, 19, 20]. 
  Dupuytren’s contracture can be related with other 
fibromatoses such as Peyronie disease, Ledderhose disease 
as well as fibromatosis of the dorsum of the proximal 
interphalangeal joints known as Garrod’s nodules or knukle 
pads. Investigations have shown that these diseases are 
identical from the histopathological perspective and patients 
who suffer from additional fibromatosis can develop new 
occurrences of the disease in different areas post operatively 
[21]. 
  DD can be classified into 3 main stages: First stage is the 
early onset of the disease where small nodules and lumps 
appear under the digits of palmer crease. In stage two the 
condition becomes more extensive and involves the fascia 
and the digits. The final and third stage is the spread of the 
disease into the fingers and the creation of strong cords 
which result in the flexion of the fingers and loss of normal 
extension [15]. 
  This disease remains mainly undetected until there is 
some flexion deformity of the digits. In the case of a certain 
diagnosis, there are two major criteria for referral and 
treatment of the patient. 1. If the contracture is becoming 
progressively worse on repeated examination and compared 
to previous history. 2. When there is a noticeable functional 
disability of the hand [15]. Dupuytren’s disease can affect 
certain activities of daily living. Among the most significant 
is face washing in which the eye is being pocked by the 
affected digit. Combing hair and putting the hand in a glove 
are also ranked as the difficulties that a patient with such a 
disease will encounter [15]. Dupuytren’s contracture deve-
lops in both hands regardless of hand dominance. The digits 
which are predominately affected are the ring finger and the 
small finger which are followed by the index, the middle 
finger and the thumb. The severity and the impact of the 
disease is different for every individual but DD presents 
more aggressively in the younger individuals when it occurs 
[15]. 
ASSESSMENT OF SUSPECTED DUPUYTREN’S 
DISEASE 
  The diagnosis of Dupuytren’s disease is often made by 
the general practitioner. Even though there are a variety of 
different causes that lead to hand contracture these do not 
present with nodules in the palm. Once the patient is referred 
to a hand specialist Orthopedic or a plastic surgeon the 
assessment initiates with a thorough history taking that 
involves gathering the most relevant information such as: 
Age, gender, ethnicity, occupation, manual hobbies, hand 
dominance, family history of this condition, age of onset, 
symptoms, disease progression, previous treatment, medical 
history of DM and epilepsy, drug history as well as 
psychosocial history [15] With the help of a detailed history 
one can predict how the disease will affect the patient’s 
occupation and by looking at the family history the post 
operative reoccurrence rate can be estimated. 
  The physical examination commences with the 
inspection of both hands in particular the affected hand. 
Great attention is given to the site of nodules, skin dimpling 
on the palm and digits, degree of skin involvement as well as 
signs of other types of fibromatoses in the hand. 
Furthermore, the patient might have previous scars in the 
palm in the case of disease recurrence [15]. 
  One useful test that greatly aids staging Dupuytren’s 
disease is the Hueston Table Top Test [22]. This is a simple 
test as the patient needs to put his/her hand prone on the 
table. If the hand does not go flat then one can say the 
Hueston Table Top Test is positive which indicates that the 
disease is in an active or moderate stage. The early stages of 
the disease are not easy to identify since Dupuytren’s disease 
starts asymptomatically. By the time the patient sees the 
doctor it is already in its moderate or severe stage. 
MATERIAL AND METHOD 
  In this review, the relevant articles were searched 
primarily from the electronic data bases AMED, ASSIA 
(CSA Illumina), CINAHL (EBSCO), Conference Procee-
dings Citation Index: Science (ISI) on Web of Knowledge, 
EMBASE, Medline, PREMEDLINE In-Process & Non-
Indexed Citations (OvidSP), PsycINFO (OvidSP), PubMed, 
Science Citation Index (ISI) on Web of Knowledge, Social 
Sciences Citation Index (ISI) on Web of Knowledge and 
Cochrane Library (Wiley) and ZETOC. The following key 
words were used for citing the appropriate articles: Dupuy-
tren’s disease _ Contracture _ assessment _ referral _ medical 
treatment  _  surgical  treatment  _  non-surgical  treatment  _ 
radiotherapy. 
  The following inclusion criteria were used to select 
relevant studies: A) Any type of surgical treatment from the 
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non surgical treatments, C) Articles experimenting new 
methods of treatment on animals for human applications. 
Articles which were excluded: A) did not include treatment 
for Dupuytren’s disease, B) Articles that were written in a 
language other than English. Out of 97 articles and studies 
that were viewed 55 were found relevant and suited the 
inclusion criteria. The relevant information from these 
articles is summarized in the result section. 
RESULT 
  According to the genetic analyses, Dupuytren’s disease is 
an autosomal dominant disorder with a variable penetrance 
and gene expression [23]. Therefore, there is no cure for this 
disease and only very few treatment options are available for 
the individuals suffering from this condition. These 
treatment options are summarized in Tables 1 and 2. The 
most commonly used treatments are surgery, open or 
percutaneus needle aponeurotomy, collagenase clostridium 
histolyticum injections, corticosteroid injections and 
radiotherapy [24] 
SURGICAL INTERVENTION 
  Surgery is the most commonly used treatment option 
which is recommended for functionally impaired patients 
with contractures more than 30° of the MP joint [25-27]. 
There is some degree of disagreement as to when surgery is 
recommended when PIP joints are affected. Certain authors 
would consider any degree of contracture of PIP joints as an 
indication for surgery. Others suggest 15° to 30° of PIP joint 
to take operation as an option [26,28]. In contrast to these 
professor McGrouther states that it is better to “rely on 
functional difficulty and the rate of progression when 
deciding on surgery, rather than choosing a set amount of 
joint contracture [29]. 
  Open, limited fasciectomy is currently ranked as the most 
commonly used surgical treatment [30-34] It is interesting to 
note that between 2003 and 2008 fasciectomy was the main 
surgical method in treatment of Dupuytren’s contracture in 
England [35]. In a limited fasciectomy the involved fascia is 
removed and in cases where the disease is not very extensive 
fasciotomy of the affected fascia is performed [15]. Even if 
surgery is the treatment of choice it does not mean that there 
are no complications associated with it. Among the most 
significant postoperative complications are haematoma, 
injuries to nerves, vascular injury, skin necrosis, oedema, 
reflex sympathetic dystrophy and amputation of the finger 
which is rare. The most common complication that patients 
encounter post operatively is joint stiffness and reduced 
flexion ability compared to their pre-operative state [29]. 
  There are two types of fasciotomies, open and closed 
fasciotomies. Open fasciotomy is the classic fasciotomy 
where the surgeon uses a scalpel to section the cords [36]. 
The closed technique or percutaneous needle aponeurotomy 
involves a minimally invasive operation with a very low 
complication rate and good short-term results in mild or 
moderate contractures [37-41] In this technique a small 
needle is used to weaken and manipulate the cords. The 
targeted cords will eventually snap very easily after being 
weakened, by simply extending the fingers passively. The 
post operative results are predominantly satisfactory but 
extensive hand therapy such as using night splints and 
regular physiotherapy exercises are required for better 
outcomes [42]. Despite its advantages studies have shown 
that percutaneous needle aponeurotomy has a high 
recurrence rate [42]. 
  When treating a patient with Dupuytren’s disease, 
surgery has the best outcome but not all individuals with 
digital contractures will benefit from it [29]. By way of 
illustration, open fasciotomy is not performed on elderly 
patients, those with co-morbidities or both. For these 
individuals closed fasciotomy or percutaneous needle 
fasciotomy can prove helpful even though the chance of 
developing this disease is very high. 
  Dermofasciectomy is the preferred procedure for the 
patients with advanced Dupuytren’s disease or patients with 
high recurrence. In this technique the skin and the affected 
fascia are both removed and the wound is grafted [21]. A 
further surgical treatment for this condition is the Jacobsen 
flap, which was first described by Jacobsen and Nielsen. 
This is a modification of McCash’s technique which was 
first performed in 1964 [43]. This modification allows the 
surgeon to expose the disease in both the palm and the 
fingers using only two linear incisions [44]. There are many 
advantages when choosing this type of surgery, for instance 
reducing the risk of developing haematoma as well as 
oedema. Furthermore, there is no need for skin grafting and 
causing additional scars on the donor site. The patient will be 
able to mobilize the hand immediately after the operation 
which reduces the risks of developing oedema. Due to the 
fact that the wound is left open, the patient has to wear a 
dynamic orthoplast splint for approximately 10 weeks in 
addition to physical therapy. The wound can easily become 
infected and thus needs to be checked and looked after very 
carefully particularly in patients who are suffering from 
diabetes mellitus and other metabolic disorders. Skin 
necrosis as well as progressive flexion deformity in the distal 
interphalangeal joint as a result of shrinking of the skin 
should also not be underestimated when considering this 
procedure [45]. Table 1 will summarize some popular 
surgical procedures and their outcomes towards treating DD. 
MEDICAL INTERVENTIONS 
  Since Dupuytren’s contracture became known to 
scientists and medical professionals numerous ways of 
treating this disease have been investigated and different 
alternatives to surgery have been found. The most effective 
non surgical treatment which has also recently got approved 
by Food and Drug Administration (FDA) is injectable 
collagenase clostridium histolyticum which is known as 
Xiaflex. Collagenase clostridium histolyticum is an enzyme 
that dissolves collagen and thus it is injected directly into the 
cord. One day post Xiaflex injection the enzyme has had 
adequate time to dissolve certain part of the collagen and this 
makes it easier for the doctor to straighten the finger 
manually. Often more than one injection is necessary to give 
the finger its previous healthy condition back. If more than 
one digit is affected then several injections spread over 
months are required. On the grounds that injecting 
collagenase clostridium histolyticum is a very new treatment 
its long-term safety and recurrence rate requires further 
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 Tomasek  et al., have investigated the effect of INF-
gamma on myofibroblast and came to the conclusion that 
INF-gamma is able to suppress the differentiation of 
myofibroblasts and thus the contractile force is being 
reduced as well. Therefore, it has the potential to be used as 
a non surgical treatment for this condition [2]. According to 
Trojian  et al., using steroid injections into the Dupuytren 
nodule in the early stages of the disease can prevent its 
progression and the need of fasciectomy. Further research 
and investigation is needed to confirm this hypothesis. 
  Another non invasive tool that can be used for treatment 
of Dupuytren’s disease is shock wave therapy. Knobloch et 
al., have primarily done a randomized-controlled trial in 
Peyronie’s disease using focused extracorporeal shock waves 
which reduced the pain and dramatically improved the 
erectile function and the quality of life. As Peyronie’s 
disease resembles Dupuytren’s to a large extent the same 
method was used in a randomized-controlled trail on 
individuals with Dupuytren’s contracture. The hypothesis is 
that focused extracorporeal shock wave therapy can be use as 
a non-invasive tool to decrease the force of contracture and 
reduce the fibromatosis of the palm [47]. It is commonly 
alleged that antiepileptic drugs such as Phenobarbital are risk 
factors for developing Dupuytren’s disease [48]. Tripoli et 
al., studied a group of patients on Phenobarbital and some 
who were on benzodiazepine and managed to find out that 
the administration of benzodiazepine reduces the risk of 
recurrence of this condition [48]. Studies have also shown 
that radiotherapy can play an important role on preventing 
the progression of the disease when applied in the early-
stages of Dupuytren’s contracture [49]. The most recent 
medical interventions for DD are demonstrated in Table 2. 
DISCUSSION 
  The first ever treatment of Dupuytren’s contracture was 
surgery which was performed by Guillaume Dupuytren and 
for many years doctors followed his way of dealing with the 
disease. Today, there are numerous ways of dealing with this 
condition and doctors can choose the most suitable method 
of treatment for their patients. Each technique has its own 
advantages and disadvantages. Certain surgical procedures 
have a very low recurrence rate such as dermofasciectomy 
[50] or Jacobsen flap [55] with a high risk of post-operative 
complication rates when compared to percutaneus needle 
aponeurotomy which has a low complication rate but a high 
rate of disease recurrence. There is a similar picture when 
looking at the non-surgical treatments, by way of illustration 
Injectable collagenase Clostridium histolyticum is an 
effective and immediate medical treatment but it is an 
expensive injection to get hold of, thus in certain countries 
where the insurance does not cover the costs patients might 
not be able to afford this treatment. Having mentioned that, 
recent statistics show that 3-5% of the UK population is 
suffering from Dupuytren’s disease and the National Health 
Service has to provide the most cost-effective treatments for 
the patients [35]. At the moment Fasciectomy and 
fasciotomy are the main treatments for Dupuytren’s 
contracture in the UK. The estimated costs for treatment of 
DD in year 2010-2011 were £41,576,141. In this year the 
costs per patient ranged from £2,736 for a day-case 
Fasciectomy to £9,210 for a day-case Revision Digital [35]. 
  Getting away from the financial side of medicine, it is 
Table 1.  Summarizes the Major Surgical Procedures for Treating DD 
 
Surgical Interventions 
Author Technique  Outcome  Complications 
Coert et al., 2006 [30]  Partial fasciectomy on 261 
patients and 7.3 years of follow 
up. 
•  Patients (age<45 ) had higher recurrence 
compared to older patients 
•  Outcome of contracted PIP joints were 
significantly worse than other joints 
•  Nerve lesions in 7.7% 
•  Higher risk of infection and 
necrosis in recurrent surgery.  
Lubahn 1999 [50]  Dermofasciectomy  •  Very low recurrence rate 
•  Reduced risk of developing haematoma as 
well as oedema. 
•  Flexion deformity in DIP joints 
•  Infections 
•  necrosis 
van Rijssen et al., 2006 [38]  percutaneous needle 
fasciotomy, a 6-week follow-up 
study, 166 rays. 
•  No major complications 
•  High patient satisfactory 
•  Good short term results 
•  High recurrence rate 
Tripoli et al.,2008 [45]  Jacobsen flap, review of 98 
cases 
A modification of McCash 
technique 
•  significant correction of the contracture 
•  Good alternative to dermofasciectomy or 
amputation. 
•  High Post operative 
complications compared to 
percutaneous needle fasciotomy 
Beaudreuil et al., 2011 [51]  Multi-needle aponeurotomy on 
30 patinets, follow up after 1 
and 6 months 
•  High post operative satisfaction 
•  Not painful 
•  safe and effective for advanced 
Dupuytren's disease 
•  No major complication 
Hovius et al., 2011 [52]  Extensive percutaneous 
aponeurotomy and lipografting 
on 99 patients 
•  Shortens recovery time 
•  Adds to the deficient subcutaneous fat 
•  Leads to scarless supple skin 
•  Digital nerve injury 
•  Postoperative wound infection 
•  Complex regional pain 
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essential to find the main cause of Dupuytren’s contracture 
in order to prevent the spread of this disease. One way could 
be to invest more time in the genetic links of this condition 
and to explore the similarities between people suffering from 
this disease. It would also be beneficial to find out the cause 
of death of these patients as they might die from similar 
conditions. One study has shown that 42% of the patients 
with severe DD died of cancer; therefore it is worth 
considering whether people having DC are more likely to 
develop neoplastic conditions. 
  Using screening programs would help to identify 
individuals with high risk of developing DD and take 
immediate measures to prevent them from developing this 
condition. However the risk of recurrence might still be the 
same, unless the origin of this disease becomes known to us. 
CONCLUSION 
  Dupuytren’s Disease is a type of fibromatoses 
characterized by nodular and distributed aggregates of 
immature fibroblasts dispersed in a dense collagen with no 
known origin. The new advances in the treatment of this 
disease are the modified and improved versions of the 
previous treatments with lower complication rates. Among 
the most recent are Multi-needle aponeurotomy, Extensive 
percutaneous aponeurotomy and lipografting, injecting 
collagenase Clostridium histolyticum, INF-gamma and 
shockwave therapy as well as Radiotherapy. Each of these 
treatments has certain advantages and drawbacks and cannot 
be used for every patient, and depending on the stage of the 
disease the treatment might alter. In order to prevent this 
condition spending more time and money in the topic is 
required to reach better and more consistent treatments and 
ultimately eradicate this disease. 
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